Lauren Miller, MPAS, and Tj Chao, MPAS, discuss key factors to consider for plaque psoriasis (PP) treatment.

Expert dermatologists present and share initial impressions of a patient case for a 6-year-old male with AD, highlighting the impact of sleep deprivation.

Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, review factors that lead to switching therapies in AD, focusing on monotherapies vs combination therapy.

An expert in dermatology shares his opinion on the multiple formulations of isotretinoin and the importance of generic vs brand compositions.

Dr Leon Kircik, discusses the novel treatment Clascoterone cream 1%, an androgen receptor agonist, and the utility of this treatment in the management of acne.

Leon Kircik, MD, shares his opinion on the role and use of treatment guidelines by healthcare practitioners in the management of their patients.

Experts discuss the role and importance of physician assistants in the treatment and care of plaque psoriasis (PP).

Tj Chao, MPAS, and Lauren Miller, MPAS, discuss the symptoms of plaque psoriasis (PP) and why it may be difficult to diagnose.

Brad Glick, DO, FAOCD, highlights topical therapy as a targeted treatment of plaque psoriasis.

Benjamin Lockshin, MD, FAAD, comments on how the evolution of the pathophysiology of plaque psoriasis has led to more targeted therapies to treat the disease.

Experts in dermatology comment on how often quickness of response to therapy determines treatment selection for teenaged patients with AD.

Expert dermatologists discuss treatment selection for short-term rescue vs long-term maintenance therapy.

Christopher Bunick, MD, PhD, comments on the role isotretinoin plays in his practice and comments on further advancements in the management of this condition.

An expert in dermatology shares his opinion on oral versus topical acne treatment options and how to assess response to treatment.

Dr Christopher Bunick discusses the role the microbiome and sebum play in acne production and highlights the role Clascoterone cream 1% plays in targeting these agents.

Christopher Bunick, MD, PhD, provides an overview of acne vulgaris and the populations it impacts; highlighting that this is more than just an adolescent affliction and the role of sebum production.

Andrew Blauvelt, MD, MBA, reviews systemic vs topical treatment of AD, discussion patient preferences as a factor for treatment selection.

Experts in dermatology discuss the rapidly expanding treatment landscape of atopic dermatitis and how these new treatment options have changed the management of AD.

An expert in dermatology reviews the differences in Isotretinoin and highlights how this treatment is both highly efficacious and safe when administered and monitored properly.

Dr Hilary Baldwin stresses the importance of defining severe acne and the utility of isotretinoin in this patient focusing on dosing and administration considerations.